[go: up one dir, main page]

AU2001260180A1 - Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients - Google Patents

Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients

Info

Publication number
AU2001260180A1
AU2001260180A1 AU2001260180A AU6018001A AU2001260180A1 AU 2001260180 A1 AU2001260180 A1 AU 2001260180A1 AU 2001260180 A AU2001260180 A AU 2001260180A AU 6018001 A AU6018001 A AU 6018001A AU 2001260180 A1 AU2001260180 A1 AU 2001260180A1
Authority
AU
Australia
Prior art keywords
active ingredients
compositions
transdermal formulations
highly lipophilic
lipophilic active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001260180A
Inventor
Adrian Funke
Clemens Gunther
Ralph Lipp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2001260180A1 publication Critical patent/AU2001260180A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition for use as penetration promoter in transdermal formulations for highly lipophilic active ingredients or active ingredient combinations, which comprises at least a first and a second penetration promoter, where the first penetration promoter is a monohydric or polyhydric alcohol, and the second penetration promoter is a saturated or unsaturated fatty acid having 8 to 18 carbon atoms or an ester or derivative thereof.
AU2001260180A 2000-04-07 2001-04-05 Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients Abandoned AU2001260180A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10019171A DE10019171A1 (en) 2000-04-07 2000-04-07 Compositions for use as penetration enhancers in transdermal formulations for highly lipophilic active ingredients
DE10019171 2000-04-07
PCT/EP2001/003896 WO2001076608A1 (en) 2000-04-07 2001-04-05 Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients

Publications (1)

Publication Number Publication Date
AU2001260180A1 true AU2001260180A1 (en) 2001-10-23

Family

ID=7639165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001260180A Abandoned AU2001260180A1 (en) 2000-04-07 2001-04-05 Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients

Country Status (8)

Country Link
US (1) US20030157155A1 (en)
EP (1) EP1267884B1 (en)
JP (1) JP2003530354A (en)
AT (1) ATE279199T1 (en)
AU (1) AU2001260180A1 (en)
DE (2) DE10019171A1 (en)
NO (1) NO20024796L (en)
WO (1) WO2001076608A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10107663B4 (en) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosterone-containing transdermal therapeutic system, process for its preparation and its use
DE10159217A1 (en) 2001-11-27 2003-06-05 Schering Ag 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations
WO2007015441A1 (en) * 2005-08-01 2007-02-08 Hisamitsu Pharmaceutical Co., Inc. Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration
DE102005050431A1 (en) * 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the administration of lipophilic and / or less skin-permeable active ingredients
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
EP2749552B1 (en) * 2007-04-17 2015-11-18 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
US8383865B2 (en) * 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
US7985776B2 (en) 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
US20100286585A1 (en) * 2009-01-26 2010-11-11 Codman & Shurtleff, Inc. Shunt Delivery of Curcumin
US7723515B1 (en) * 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
EP2258375A1 (en) 2009-06-04 2010-12-08 Bayer Schering Pharma Aktiengesellschaft 17B-alkyl-17alpha-oxy-estratrienes
ES2744454T3 (en) 2013-10-31 2020-02-25 Hisamitsu Pharmaceutical Co Adjuvant composition

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4559054A (en) * 1984-08-09 1985-12-17 Research Corporation Rate-controlled drug release system
US4789547A (en) * 1987-06-17 1988-12-06 Warner-Lambert Company Transdermal matrix system
JP3238389B2 (en) * 1988-10-27 2001-12-10 シエーリング アクチエンゲゼルシヤフト Drugs for transdermal applications containing gestodene
DE3910578A1 (en) * 1989-03-29 1990-10-04 Schering Ag Composition for transdermal administration containing gestodene
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4891377A (en) * 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
US5788983A (en) * 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
AR246186A1 (en) * 1989-11-17 1994-07-29 Beta Pharm Co Procedure for manufacturing a device for administering stradiol through the skin.
JPH05946A (en) * 1991-06-27 1993-01-08 Nichiban Co Ltd Ketotifen-containing percutaneous absorption preparation
DE4210165A1 (en) * 1991-07-30 1993-02-04 Schering Ag TRANSDERMAL THERAPEUTIC SYSTEMS
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
AU3595393A (en) * 1992-01-31 1993-09-01 Cygnus Therapeutic Systems Transdermal administration of buprenorphine in the form of ion pair complexes
JP2960832B2 (en) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト Estradiol administration system
CA2101496A1 (en) * 1992-07-31 1994-02-01 Masao Kobayashi Base for transdermal administration
DE4329242A1 (en) * 1993-08-26 1995-03-02 Schering Ag Agent for transdermal application containing gestodenester
HU221432B (en) * 1994-02-04 2002-10-28 Lipocore Holding Ab Lipophilic carrier preparations
CN1106259A (en) * 1994-02-05 1995-08-09 日东制药株式会社 Antiphlogistic and analgesic gel agent for external use containing propanoic acid non steroid pharmaceutical as effective composition
DE4405899A1 (en) * 1994-02-18 1995-08-24 Schering Ag Agent for transdermal application containing desogestrel
JPH07252150A (en) * 1994-03-14 1995-10-03 T T S Gijutsu Kenkyusho:Kk Percutaneous absorption type preparation containing ozagrel
JPH08245377A (en) * 1995-03-15 1996-09-24 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for percutaneous absorption
DE19613698A1 (en) * 1995-07-17 1997-01-23 Schering Ag Agent for transdermal application containing esters of 13-ethyl-17β-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
IT1283102B1 (en) * 1996-06-06 1998-04-07 Permatec Nv THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES
US5669377A (en) * 1996-07-05 1997-09-23 Fenn; Arthur C. Nasal band and method for improved breathing
DE19629468A1 (en) * 1996-07-11 1998-01-15 Schering Ag Transdermal therapeutic systems
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19635525A1 (en) * 1996-08-20 1998-02-26 Schering Ag New 7-alpha-(xi-aminoalkyl)- oestratriene derivatives
DE19842123C1 (en) * 1998-09-05 2000-07-13 Schering Ag 11beta-fluoro-7alpha- (14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl) estra-1,3,5 (10) - triene-3,17beta-diol as crystalline solvate

Also Published As

Publication number Publication date
NO20024796L (en) 2002-12-06
EP1267884B1 (en) 2004-10-13
DE60106406D1 (en) 2004-11-18
JP2003530354A (en) 2003-10-14
US20030157155A1 (en) 2003-08-21
WO2001076608A1 (en) 2001-10-18
EP1267884A1 (en) 2003-01-02
ATE279199T1 (en) 2004-10-15
NO20024796D0 (en) 2002-10-04
DE10019171A1 (en) 2001-10-18
DE60106406T2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
AU2001260180A1 (en) Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients
GB2308546B (en) Topical macrolide compositions
SI1313510T1 (en) Injectable pharmaceutical composition for systemic delivery of pharmacologically active compounds comprising medium chain triglycerides
WO2002011552A3 (en) Oil/fat composition
NZ512287A (en) Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester
MY111841A (en) Injectable liposomal pharmaceutical preparations
KR950007873A (en) Biologics Sustained-Release Pharmaceutical Formulations
AU3443200A (en) Compositions containing boswellia extracts
GB2363721A (en) Skin-friendly absorbent articles and compositions
KR940005267A (en) Percutaneous administration base
CA2360300A1 (en) A transdermal composition of an antivomiting agent and a preparation containing the same
EP0985412A3 (en) Cyclosporin compositions
EP0773028A4 (en) PREPARATION SUITABLE FOR PERCUTANEOUS ABSORPTION
WO1993009760A3 (en) Dermatological and cosmetic compositions
GB2367490A (en) Skin barrier enhancing absorbent tissues
EP1219288A3 (en) Treatment for skin
WO1995023586A3 (en) Cosmetic and/or pharmaceutical preparations
DK1151755T3 (en) Pharmaceutical preparation containing cyclosporin as active ingredient
WO2007051830A3 (en) Composition for the transdermal administration of physiologically active agents
WO2003035966A3 (en) Water-free preparation and use thereof as brightening agent for sewing thread
MX9708104A (en) Immunostimulating-wound healing compositions and methods for preparing and using same